Psychedelic Stroke Research
What we are asking, and what we can't yet show.
The Stroke Recovery Question
Stroke recovery research generally measures what a person can demonstrate during an assessment.
We are interested in a question sitting next to that one: whether a person re-enters their own life – whether they initiate, practice and participate more in something they chose themselves. Think of it related to executive functioning.
We’re not dismissing functional measurement. Impairment is real, function matters, and the instruments that measure it are useful.
It is a claim about sufficiency, not validity: meaningful recovery is not exhausted by any single measure, and the parts that fall outside are not soft. They are where a great deal of the suffering sits.
That framing is not only ours.
A 2019 systematic review of survey studies found that, on average, roughly three-quarters of stroke survivors reported at least one unmet need after discharge, with wide variation across studies.
A 2025 qualitative study of 30 stroke survivors and 11 caregivers identified five constructs associated with quality of life after stroke. A widely used stroke quality-of-life measure captured reduced physical functioning and reduced participation well, while internal states – loss of independence, feelings of shame, and fear of uncertainty – were not fully captured.
The authors described this as a potential gap in understanding patient-centered outcomes after stroke.
That gap is part of what PSI wants to understand better.
What PSI Is Actually Planning
Two projects, early conversations.
A retrospective survey of stroke survivors who have already used psychedelics during their recovery, looking for real-world evidence of whether there is any signal worth pursuing.
Recovery-activation study concept, developed with a research psychologist, testing participation in a self-chosen activity as a primary outcome rather than performance in an assessment.
The underlying question is whether survivor-centered outcomes such as agency, participation and re-engagement in life can add something meaningful to conventional stroke recovery measures.
Concept stage. No protocol, no funding, no site, no regulatory pathway.
Neither project has ethics/IRB approval, funding or a site.
What the Psychedelic Stroke Evidence Does, and Does Not, Establish
The full account is on our Psychedelics After Stroke page.
In summary:
Human evidence, other conditions. Psilocybin has produced significant reductions in depression symptoms in randomized human trials, including major depressive disorder and depression and anxiety associated with life-threatening cancer. These interventions included psychological support and did not study stroke recovery.
Preclinical stroke evidence. DMT reduced infarct size and improved functional recovery in a rat model of transient ischemic stroke. Subsequent work reported effects on cerebral edema, blood-brain-barrier integrity and neuroinflammation. A separate psilocybin rat study reported reduced infarction and improved locomotor behavior.
These findings are meaningful preclinical signals. They are also largely acute animal models and do not establish that psychedelics improve chronic stroke recovery in humans.
Preclinical plasticity evidence. Multiple animal and cell studies report structural plasticity effects from psychedelics. Human evidence is more complicated and remains under development.
Human stroke evidence. A Phase 1 Johns Hopkins study is recruiting people with chronic stroke to evaluate the safety and tolerability of psilocybin. Its safety monitoring is heavily cardiovascular. No results are posted. PSI has no involvement in the study.
In the research we have reviewed to date, we have not identified human evidence demonstrating that a psychedelic improves a stroke outcome.
The Findings That Argue Against Us
We list these because a research page that omitted them would not be worth reading.
A 2026 human PET study of fifteen healthy volunteers found no statistically significant overall increase in its measure of synaptic density one week after psilocybin.
Another 2026 human study found some lasting anatomical changes and increased cognitive flexibility after high-dose psilocybin, while enduring functional brain changes were largely absent.
A widely cited 2018 neuritogenesis study found no effect from ibogaine in its assay. More recent preclinical work using different methods has reported neuronal growth effects, meaning that literature is not one-directional.
Mouse research on psychedelic-induced critical periods found that the duration of reopening tracked the duration of acute drug effects — raising questions about whether sub-perceptual dosing should be assumed to produce the same plasticity effects.
The published DMT–stroke literature remains small and concentrated in relatively few research groups.
Whether and how much the chronic post-stroke brain retains a therapeutically meaningful window for enhanced recovery remains an active question in rehabilitation science.
Psilocybin is not FDA-approved as a medication in the United States.
How PSI Handles Evidence
Four commitments, which we would like to be held to.
We state the evidence level and the population. Mechanistic plausibility does not become demonstrated effect. Preclinical work does not become human efficacy. A case observation does not become generalizable evidence.
We preserve disagreement. Where credible evidence conflicts, both stay visible.
We publish negative results, including our own.
We scope absence claims to what we have actually reviewed. We say “we have not identified” rather than “there is none,” because our reading is not a complete map of the literature.
Where PSI develops formal research, we intend to use established stroke research definitions and trial-development frameworks, define outcomes in advance, and preregister where appropriate.
For Clinicians: When a Patient Asks About Psychedelics After Stroke
It’s happening more and more, and there is not much written specifically for you.
What we can tell you. We haven’t yet identified human efficacy evidence for psychedelics in stroke recovery. The strongest human efficacy evidence comes from psychiatric populations, generally with psychological support as part of the intervention. The existing stroke animal literature does not establish efficacy in chronic human stroke.
A Phase 1 psilocybin study (John’s Hopkins) in chronic stroke is currently focused on safety and tolerability.
Is it happening anecdotally in the real world? 100% – but we can’t say for certain what/if any role psychedelics truly played.
What we think is genuinely useful to you. Cardiovascular safety is one of the cornerstones. Psychedelics can acutely affect blood pressure and heart rate, and direct evidence in stroke survivors – particularly those with vascular disease, seizure risk, or medications affecting coagulation or cardiovascular function – remains sparse.
What we are not. We do not advise on patient management, supply substances.
If a patient of yours is going to explore this regardless – which happens – we would rather they did it having had the conversation with you, and we encourage you share with PSI with them, our support groups, or additional materials found here on the site.
If you think we have something wrong, an idea for improvement, or collaboration, we would like to hear it.
Start a Conversation
For Stroke & Psychedelic Researchers
What we think PSI can contribute:
The ability to reach stroke survivors already having these experiences outside research settings. Survivor-defined outcome development. Real-world evidence and structured case documentation. And a genuine willingness to publish findings that do not favor our hypotheses.
What we do not have:
Ethics infrastructure, a principal investigator, funding, or a research site.
We are working toward the infrastructure required for credible inquiry and will not describe it as complete before it is.
We are in exploratory conversations with academic groups about future work.
None is a confirmed collaboration, and we will not name anyone until it is one – which is also how we would treat your name.
Start a Conversation
For Funders & Partners: What PSI Is Structurally
Stated plainly, straight from us.
Psychedelic Stroke Institute is a Colorado nonprofit corporation.
It does not currently hold IRS 501(c)(3) recognition. An EIN has been issued; an EIN is not tax-exempt status.
It is exploring fiscal sponsorship. Conversations are in progress. Nothing is agreed.
Founded and run by a stroke survivor and Colorado state licensed natural medicine facilitator. We do not yet have a complete (2/3 currently) independent board.
Governance work – including conflict-of-interest policy, ethics principles and independent oversight – is underway.
What that means for you.
We are early. Foundation building.
If you are looking for an organization with established clinical research infrastructure already in place, that is not us yet.
If you are interested in psychedelic stroke research, survivor-centered outcomes, real-world evidence, and an organization that will make a fundamental impact on the human condition, we would like to talk.